Ventricular tachycardia (VT) has a destructive effect on people's health and heart. VT is a major cause of mortality among patients with cardiovascular diseases. The drug treatment of VT is highly sensitive and is selected according to the patient's condition. A 42-year-old man was admitted to the emergency department with dyspnea, Levine sign, and severe chest pain. His EKG showed ST elevation, and the QT interval was normal. The patient was sent to the cath lab based on the treatment protocols. According to the results of angiography, three coronary arteries were severely obstructed. His coronary arteries did not open during PCI; thus, the healthcare team decided on open heart surgery. He suffered from recurrent polymorphic VT following open heart surgery and did not respond to any of the drugs suitable for this type of tachycardia. Inderal prevented the recurrence of VT in a patient with polymorphic VT, which, contrary to the healthcare team's expectations. Inderal was used as the last line of treatment because this patient's arrhythmia was polymorphic VT. Inderal is mainly used in monomorphic VT and in patients with heart structure disorders. The result of the present study demonstrates the effect of the antiarrhythmic drug Inderal on polymorphic VT.